Drug Profile
Research programme: dengue fever DNA vaccines - Inovio
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Inovio Biomedical Corporation
- Developer Inovio Pharmaceuticals
- Class Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dengue